Mast Therapeutics (NYSEMKT:MSTX) has been downgraded from Buy to Hold in a report by Maxim Group today.
- Updated: September 21, 2016
Having a price of $0.59, Mast Therapeutics (NYSEMKT:MSTX) traded -81.54% lower on the day. With the last stock price close up -71.25% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. MSTX has recorded a 50-day average of $0.46 and a two hundred day average of $0.38. 91,781,043 shares of MSTX traded hands, up from an average trading volume of 4,271,440
Maxim Group has downgraded Mast Therapeutics (NYSEMKT:MSTX) from Buy to Hold in a report released on 9/21/2016.
On 11/12/2015, Maxim Group released a statement on Mast Therapeutics (NYSEMKT:MSTX) bumped up the target price from $0.00 to $5.00. At the time, this indicated a possible upside of 10.90%.
Mast Therapeutics has a with a one year low of $0.11 and a one year high of $0.71 The company’s market cap is currently $0.
About Mast Therapeutics (NYSEMKT:MSTX)
Mast Therapeutics, Inc. is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options. The Company's segment is engaged in the business of developing therapies for serious or life-threatening diseases. The Company focuses on its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, its lead product candidate. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. The Company's AIR001 is in Phase II clinical development for the treatment of patients with HFpEF.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.